Biogen Idec, Orphan Biovitrum partner for hemophilia B drug trial

Biogen Idec is collaborating with Orphan Biovitrum on a clinical trial to evaluate the safety and efficacy of a recombinant Factor IX Fc fusion protein in preventing bleeding in hemophilia B patients. Biogen Idec also received FDA approval to market Ampyra, a multiple sclerosis drug it owns with Acorda Therapeutics.

View Full Article in:

Mass High Tech (Boston) · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL